CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.70
0.00 (0.00%)
Oct 3, 2025, 4:00 PM EDT - Market open
CervoMed Revenue
CervoMed had revenue of $1.76M in the quarter ending June 30, 2025, a decrease of -46.56%. This brings the company's revenue in the last twelve months to $7.78M, down -19.44% year-over-year. In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth.
Revenue (ttm)
$7.78M
Revenue Growth
-19.44%
P/S Ratio
9.81
Revenue / Employee
$518,465
Employees
15
Market Cap
80.50M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
Dec 31, 2023 | 7.14M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 4 days ago - CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - GlobeNewsWire
- 19 days ago - CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference - GlobeNewsWire
- 4 weeks ago - CervoMed to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - CervoMed's Dementia Data Show Slowed Disease Progression - Benzinga
- 2 months ago - CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration - GlobeNewsWire
- 3 months ago - CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025 - GlobeNewsWire
- 5 months ago - CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 months ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha